- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Peptide firm Diatide to go public
Peptide imaging agent developer Diatide of Londonderry, NH, planson issuing an initial public offering in the next several weeksthat will raise $25 million to fund ongoing product development.The firm will price its stock at $10 to $12 a share,
Peptide imaging agent developer Diatide of Londonderry, NH, plans
on issuing an initial public offering in the next several weeks
that will raise $25 million to fund ongoing product development.
The firm will price its stock at $10 to $12 a share, according
to president Richard Dean. Diatide's lead product is a technetium-99m-labeled
agent for detection of deep vein thrombosis.
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).
